参考文献/References:
[1] 左文述,徐忠法,刘奇.现代乳腺肿瘤学.2版.济南:山东科学技术出版社,2006:425.
[2] Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst, 2000, 92(3):205-216.
[3] Londero V, Bazzocchi M, Del Frate C, et al. Locally advanced breast cancer:comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy. Eur Radiol, 2004, 14(8):1371-1379.
[4] Huber S, Medl M, Helbich T, et al. Locally advanced breast carcinoma:computer assited semiqutitative analysis of color Doppler uhrasonography in the evaluation of tumor response to neoadjuvant chemotherapy (work in progress). J Ultrasound Med, 2000, 19(9):601-607.
[5] Kuerer HM, Newman LA, Buzdar AU, et al. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. Am J Surg, 1998, 176(6):502-509.
[6] Londero V, Bazzocchi M, Ded Frate C, et al. Locally advanced breast cancer:comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy. Eur Radiol, 2004, 14(8):1371-1379.
[7] Delille JP, Slanetz PJ, Yeh ED, et al. Invasive ductal breast carcinoma response to neoadjuvant chemotherapy:noninvasive monitoring with functional MR Imaging pilot Study. Radiology, 2003, 228(1):63-69.
[8] 顾雅佳,冯晓源,邱龙华,等.DWI对局部进展期乳腺癌新辅助化疗疗效评价的初步研究.放射学实践,2007,22(12):1249-1255.
[9] 汪晓红,彭卫军,沈坤炜,等.fMRI监测乳腺癌新辅助化疗疗效的应用.放射学实践,2007,22(11):1135-1138.
[10] Pickles MD, Lowry M, Manton DJ, et al. Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy. Breast Cancer Res Treat, 2005, 91(1):1-10.
[11] 张晓鹏,李洁,孙应实,等.动态增强磁共振成像对乳腺癌新辅助化疗后病理反应性的术前评价.中国医学科学院学报,2008,30(1):98-103.
[12] Rieber A, Zeitler H, Rosenthal H, et al. MR1 in breast cancer:influence of chemotherapy on sensitivity. Br J Radiol, 1997, 70(833):452-458.
[13] Warren RM, Bobrow LG, Earl HM, et al. Can breast MRI help in the management of women with breast cancer treated by neoadjuvant chemotherapy?. Br J Cancer, 2004, 90(7):1349-1360.
[14] Rajan R, Poniecka A, Smith TL, et al. Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response. Cancer, 2004, 100(7):1365-1373.
[15] Martincich L, Montemurro F, De Rosa G, et al. Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging. Breast Cancer Res Treat, 2004, 83(1):67-76.
[16] 朱汇庆,林祥通,陈忠清,等.乳腺肿瘤摄取99Tcm-MIBI与预后因子的关系.中华核医学杂志,2002,22(1):19-21.
[17] Dunnwald LK, Gralow JR, Ellis GK, el al. Residual tumor uptake of 99mTc-sestamibi after neoadjuvant chemotherapy for locally advanced breast carenoma prediets survival. Cancer, 2005, 103(4):680-688.
[18] Takeuchi N, Fukumoto M, Nishioka A, et al. Seintigraphic prediction of response to chemotherapy in patients with breast cancer:Technetium 99m-tetrofosmin and thallium-201 dual single photon emission computed tomography. Int J Oncol, 2002, 20(1):53-58.
[19] Dunnwald LK, Gralow JR, Ellis GK, et al. Tumor metabolism and blood flow changes by positron emission tomography:relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol, 2008, 26(27):4449-4457.
[20] Mankoff DA, Dunnwald LK, Gralow JR, et al. Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. J Nucl Med, 2003, 44(11):1806-1814.
[21] Smyczek-Gargya B, Fersis N, Dittmann H, et al. PET with[18F] fluorothymidine for imaging of primary breast cancer:a pilot study. Eur J Nucl Med Mol Imaging, 2004, 31(5):720-724.
[22] Been LB, Elsinga PH, de Vries J, et al. Positron emission tomography in patients with breast cancer using 18F-3’-deoxy-3’-fluoro-L-thymidine (18F-FLT)-a pilot study. Eur J Surg Oncol, 2006, 32(1):39-43.
[23] Pio BS, Park CK, Pietras R, et al. Usefulness of 3’-[F-18] fluoro-3’-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol, 2006, 8(1):36-42.
[24] Wahl RL, Zasadny K, Helvie M, et al. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography:initial evaluation. J Clin Oncol, 1993, 11(11):2101-2111.
[25] Weber WA. Positron emission tomography as an imaging biomarke. J Clin Oncol, 2006, 24(20):3282-3292.
[26] Schelling M, Avril N, Nährig J, et al. Positron emission tomography using [18F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol, 2000, 18(8):1689-1695.
[27] Rousseau C, Devillers A, Sagan C, et al. Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography. J Clin Oncol, 2006, 24(34):5366-5372.
[28] McDermott GM, Welch A, Staff RT, et al. Monitoring primary breast cancer throughout chemotherapy using FDG-PET. Breast Cancer Res Treat, 2007, 102(1):75-84.
[29] Doot RK, Dunnwald LK, Schubert EK, et al. Dynamic and static approaches to quantifying 18F-FDG uptake for measuring cancer response to therapy, including the effect of granulocyte CSF. J Nucl Med, 2007, 48(6):920-925.
相似文献/References:
[1]周玉祥,蓝博文,黄春榆,等.64排螺旋CT冠状动脉血管成像诊断冠状动脉-肺动脉瘘的应用价值[J].国际放射医学核医学杂志,2016,40(1):26.[doi:10.3760/cma.j.issn.1673-4114.2016.01.006]
Zhou Yuxiang,Lan Bowen,Huang Chunyu,et al.Clinical value of coronary artery-pulmonary artery fistula revealed by 64-slice spiral CT coronary angiography[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):26.[doi:10.3760/cma.j.issn.1673-4114.2016.01.006]
[2]陈超坤,刘亮,傅飞先,等.囊性胸腺瘤和囊性畸胎瘤的影像学特征及鉴别诊断[J].国际放射医学核医学杂志,2016,40(1):31.[doi:10.3760/cma.j.issn.1673-4114.2016.01.007]
Chen Chaokun,Liu Liang,Fu Feixian,et al.Imaging features and differential diagnosis of cystic thymoma and cystic teratoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):31.[doi:10.3760/cma.j.issn.1673-4114.2016.01.007]
[3]岳进,苏丽萍.全身MRI与PET/CT在淋巴瘤骨髓浸润诊断及预后中的作用[J].国际放射医学核医学杂志,2016,40(1):50.[doi:10.3760/cma.j.issn.1673-4114.2016.01.010]
Yue Jin,Su Lipin.Function of whole-body MRI and PET/CT in the diagnosis and prognosis of lymphoma with bone marrow infiltration[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):50.[doi:10.3760/cma.j.issn.1673-4114.2016.01.010]
[4]张莹莹,王振光,孔艳.PET/CT显像在肺间质纤维化中的应用进展[J].国际放射医学核医学杂志,2016,40(1):55.[doi:10.3760/cma.j.issn.1673-4114.2016.01.011]
Zhang Yingying,Wang Zhenguang,Kong Yan.Application advancement on PET/CT in pulmonary interstitial fibrosis[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):55.[doi:10.3760/cma.j.issn.1673-4114.2016.01.011]
[5]麦卫平,张永林.能谱CT成像在肺癌诊断中的应用研究进展[J].国际放射医学核医学杂志,2016,40(1):77.[doi:10.3760/cma.j.issn.1673-4114.2016.01.015]
Mai Weiping,Zhang Yonglin.Research progress of spectral imaging in the diagnosis of lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):77.[doi:10.3760/cma.j.issn.1673-4114.2016.01.015]
[6]杨雷,袁卫红,王家平,等.99Tcm-MIBI显像与钼靶X线对乳腺癌诊断的比较研究[J].国际放射医学核医学杂志,2016,40(2):111.[doi:10.3760/cma.j.issn.1673-4114.2016.02.005]
Yang Lei,Yuan Weihong,Wang Jiaping,et al.Diagnostic value of technetium 99Tcm sestamibi and X-ray mammography in breast cancer: a comparison study[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):111.[doi:10.3760/cma.j.issn.1673-4114.2016.02.005]
[7]史文杰,孟召伟,谭建.基于Deauville标准探讨18F-FDG PET/CT在霍奇金淋巴瘤复发诊断中的应用价值[J].国际放射医学核医学杂志,2016,40(2):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
Shi Wenjie,Meng Zhaowei,Tan Jian.Value of 18F-FDG PET/CT on diagnosis of Hodgkin lymphoma recurrence using Deauville criterion[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
[8]马乐,张万春,李晓敏.乳腺癌前哨淋巴结核素显像新进展[J].国际放射医学核医学杂志,2016,40(2):145.[doi:10.3760/cma.j.issn.1673-4114.2016.02.012]
Ma Le,Zhang Wanchun,Li Xiaomin.Evolution of radionuclide imaging of sentinel node lymphscintigraphy in breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):145.[doi:10.3760/cma.j.issn.1673-4114.2016.02.012]
[9]周翠屏,廖俊杰,何国华,等.原发性肠系膜巨大淋巴结增生症的MSCT表现与病理对照分析[J].国际放射医学核医学杂志,2016,40(3):175.[doi:10.3760/cma.j.issn.1673-4114.2016.03.003]
Zhou Cuiping,Liao Junjie,He Guohua,et al.Primary mesenteric Castleman disease:MSCT findings with histopathologic correlation[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):175.[doi:10.3760/cma.j.issn.1673-4114.2016.03.003]
[10]张巧娜,刘汉东.上颌窦上皮-肌上皮癌的CT表现一例[J].国际放射医学核医学杂志,2016,40(3):237.[doi:10.3760/cma.j.issn.1673-4114.2016.03.015]
[11]胡鸿,唐刚华,聂大红.乳腺癌分子显像研究进展[J].国际放射医学核医学杂志,2015,39(1):91.[doi:10.3760/cma.j.issn.1673-4114.2015.01.019]
Hu Hong,Tang Ganghua,Nie Dahong.Progress on molecular imaging of breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):91.[doi:10.3760/cma.j.issn.1673-4114.2015.01.019]
[12]李雯,冯彦林.18F-FDG PET/CT评估三阴性乳腺癌新辅助化疗疗效的研究进展[J].国际放射医学核医学杂志,2014,38(3):197.[doi:10.3760/cma.j.issn.1673-4114.2014.03.013]
Li Wen,Feng Yanlin.Advances of assessment with 18F-FDG PET/CT in triple-negative breast cancer during neoadjuvant chemotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):197.[doi:10.3760/cma.j.issn.1673-4114.2014.03.013]
[13]胡梦裳,章斌.PET/CT显像在乳腺癌疗效评价及预后中的作用[J].国际放射医学核医学杂志,2014,38(5):332.[doi:10.3760/cma.j.issn.1673-4114.2014.05.013]
Hu Meng-shang,Zhang Bin.The role of PET/CT imaging in the evaluation of the efficacy and prognosis of breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):332.[doi:10.3760/cma.j.issn.1673-4114.2014.05.013]
[14]王宇峰,刘海娜,张居洋,等.SPECT/CT融合显像对乳腺癌骨转移的诊断价值[J].国际放射医学核医学杂志,2014,38(6):387.[doi:10.3760/cma.j.issn.1673-4114.2014.06.010]
Wang Yu-feng,Liu Hai-na,Zhang Ju-yang,et al.Clinical value of SPECT/CT fusion imaging in diagnosing metastatic bone lesions in breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):387.[doi:10.3760/cma.j.issn.1673-4114.2014.06.010]
[15]董佳佳,章斌.多种影像学方法评价乳腺癌新辅助化疗疗效的价值比较[J].国际放射医学核医学杂志,2014,38(6):427.[doi:10.3760/cma.j.issn.1673-4114.2014.06.018]
Dong Jia-jia,Zhang Bin.Comparision on the values of different image modalities in monitoring the response to neoadjuvant chemotherapy in breast cancer patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):427.[doi:10.3760/cma.j.issn.1673-4114.2014.06.018]
[16]袁建伟,杨劼,贺小红,等.乳腺癌18F-FDG PET/CT和3.0T MRI联合显像评分与Ki-67表达水平的相关性分析[J].国际放射医学核医学杂志,2013,37(2):84.[doi:10.3760/cma.j.issn.1673-4114.2013.02.006]
YUAN Jian-wei,YANG Jie,HE Xiao-hong,et al.Correlation between combined imaging modalities of 18F-FDG PET/CT and 3.0T MRI and expression of Ki-67 in breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(3):84.[doi:10.3760/cma.j.issn.1673-4114.2013.02.006]
[17]袁建伟,杨劼,贺小红,等.18F-FDG PET/CT与3.0T MRI联合显像在乳腺癌原发病灶诊断中的价值[J].国际放射医学核医学杂志,2013,37(4):199.[doi:10.3760/cma.j.issn.1673-4114.2013.04.003]
YUAN Jian-wei,YANG Jie,HE Xiao-hong,et al.Diagnosis value of 18F-FDG PET/CT and 3.0T MRI combined imaging in detecting the primary focus of breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(3):199.[doi:10.3760/cma.j.issn.1673-4114.2013.04.003]
[18]林美福,陈文新,周硕,等.18F-FES PET/CT显像在雌激素受体阳性乳腺癌诊疗中的初步应用[J].国际放射医学核医学杂志,2013,37(4):216.[doi:10.3760/cma.j.issn.1673-4114.2013.04.007]
LIN Mei-fu,CHEN Wen-xin,ZHOU Shuo,et al.Application of 18F-FES PET/CT in diagnosis and endocrine therapy of patients with estrogen receptorpositive breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(3):216.[doi:10.3760/cma.j.issn.1673-4114.2013.04.007]
[19]樊孝廉,鲁胜男,古炎发,等.乳腺癌患者骨病灶SPECT/CT融合显像的临床价值[J].国际放射医学核医学杂志,2013,37(4):221.[doi:10.3760/cma.j.issn.1673-4114.2013.04.008]
FAN Xiao-lian,LU Sheng-nan,GU Yan-fa,et al.The clinical value of SPECT/CT fusion imaging in the diagnosis of bone metastasis of breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(3):221.[doi:10.3760/cma.j.issn.1673-4114.2013.04.008]
[20]柳杰,刘佩芳.乳腺癌X射线征象与雌激素受体、孕激素受体和C-erbB-2表达相关性的研究进展[J].国际放射医学核医学杂志,2012,36(5):301.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.009]
LIU Jie LIU,Pei-fang.Development of the correlation study between mammographic appearances and expression of estrogen receptor, progesterone receptor and C-erbB-2 in patients with breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(3):301.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.009]